<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPX</journal-id>
<journal-id journal-id-type="hwp">sptpx</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Pathol</journal-id>
<journal-title>Toxicologic Pathology</journal-title>
<issn pub-type="ppub">0192-6233</issn>
<issn pub-type="epub">1533-1601</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0192623311428478</article-id>
<article-id pub-id-type="publisher-id">10.1177_0192623311428478</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Session 2: Innate Immunity</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Crosstalk between Complement and Toll-Like Receptors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Song</surname>
<given-names>Wen-Chao</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623311428478"/>
<xref ref-type="corresp" rid="corresp1-0192623311428478"/>
</contrib>
</contrib-group>
<aff id="aff1-0192623311428478">Institute for Translational Medicine and Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</aff>
<author-notes>
<corresp id="corresp1-0192623311428478">Wen-Chao Song, PhD, University of Pennsylvania School of Medicine, Room 1254 BRBII/III, 421 Curie Blvd., Philadelphia, PA 19104; e-mail: <email>songwe@upenn.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>40</volume>
<issue>2</issue>
<fpage>174</fpage>
<lpage>182</lpage>
<permissions>
<copyright-statement>© Society of Toxicologic Pathology 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society of Toxicologic Pathology</copyright-holder>
</permissions>
<abstract>
<p>The complement system and toll-like receptors (TLRs) are two components of innate immunity that are critical for first-line host defense. Many pathogen-associated molecular patterns activate both complement and TLRs, and recent studies in animal models have revealed a marked synergistic interaction between the two systems. In mice deficient in a membrane complement regulator, prototypical TLR ligands such as LPS, zymosan, and polyI:C caused increased systemic complement activation, which in turn led to a profound elevation of proinflammatory cytokine biosynthesis. This phenotype required interaction between complement and TLRs because complement activation alone by cobra venom factor without TLR engagement did not lead to appreciable cytokine production. The regulatory effect of complement on TLR signaling was mediated by the anaphylatoxins C5a and C3a through a receptor-dependent mechanism and involved increased mitogen-activated protein kinase and nuclear factor κB activation. The crosstalk between complement and TLRs may also impact adaptive immunity, for example, the differentiation of T helper 17 (Th-17) cells. Given that excessive activation of either TLR or complement has been associated with inflammatory tissue injury as occurs in sepsis and autoimmune diseases, the new insight on complement and TLR crosstalk may have therapeutic implications.</p>
</abstract>
<kwd-group>
<kwd>complement; TLR; innate immunity; inflammation; cytokines.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0192623311428478">
<title>Complement</title>
<p>Complement is a major component of innate immunity that plays a crucial role in host defense (<xref ref-type="bibr" rid="bibr15-0192623311428478">Dunkelberger and Song 2010a</xref>). It is composed of over thirty proteins in the plasma and on the cell surface. Complement is activated in a cascade of proteolytic reactions via three different pathways: the classical, alternative, and mannose-binding lectin (MBL) pathways (<xref ref-type="fig" rid="fig1-0192623311428478">Fig. 1</xref>). The classical pathway is triggered by antibody-antigen complexes and requires the participation of C1, C2, and C4. Activation of the classical pathway generates a C3-cleaving enzyme complex called the classical pathway C3 convertase, C4b2a. The MBL pathway is activated upon recognition of specific sugar molecules on microbial surfaces by lectins. It uses MBL-associated serine proteases (MASPS) as well as C2 and C4 to generate the same C3 convertase (C4b2a) as in the case of classical pathway of complement activation. The alternative pathway is thought to be constitutively active at a low level due to spontaneous hydrolysis of C3. Hydrolyzed C3 interacts with factor B and factor D to initiate the alternative pathway and subsequently generates the alternative pathway C3 convertase C3bBb. The latter enzyme complex, which is also formed ultimately as a result of classical pathway and MBL pathway complement activation, is self-perpetuating and works to rapidly amplify complement activation, regardless of the pathway by which complement activation is initiated. Newly formed C3bBb is a labile complex, and its half-life is extended by the plasma protein properdin. Recent studies have shown that properdin could also play a role in the initiation of alternative pathway complement activation, likely in an activating surface- and animal species–specific manner (<xref ref-type="bibr" rid="bibr42-0192623311428478">Kemper, Atkinson, and Hourcade 2010</xref>; Hourcase 2006; <xref ref-type="bibr" rid="bibr71-0192623311428478">Spitzer et al. 2007</xref>; <xref ref-type="bibr" rid="bibr44-0192623311428478">Kimura et al. 2008</xref>; <xref ref-type="bibr" rid="bibr1-0192623311428478">Agarwal et al. 2010</xref>; <xref ref-type="bibr" rid="bibr21-0192623311428478">Ferreira, Cortes, and Pangburn 2010</xref>).</p>
<fig id="fig1-0192623311428478" position="float">
<label>Figure 1</label>
<caption>
<p>Complement activation cascade. Complement can be activated by three pathways in a cascade of proteolytic reactions. All pathways converge at the C3 cleavage step from which an alternative pathway amplification loop involving C3bBb is engaged. Proteolytic enzyme activity is indicated by block arrows. The C3 convertases are indicated by an oval box, and C5 convertases are indicated by a rectangular box. Effector functions of activated complement are indicated by star boxes (orange for anaphylatoxins, black for opsonization by activated C3 fragments, and blue for membrane attack complex).</p>
</caption>
<graphic alternate-form-of="fig1-0192623311428478" xlink:href="10.1177_0192623311428478-fig1.tif"/>
</fig>
<fig id="fig2-0192623311428478" position="float">
<label>Figure 2</label>
<caption>
<p>Interaction between complement and the TLR pathways. Pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), zymosan, and CpGs can activate both pathways. Activated complement regulates Toll-like receptor (TLR) signaling through the activities of G protein-coupled anaphylatoxin receptors C5aR and C3aR, intracellular signaling molecules such as MAPKs, and transcriptional factors such as NF-kB. In the absence of the complement regulatory protein decay-accelerating factor (DAF), complement activation and its effect on TLR signaling is amplified. The absence of DAF may be mimicked by strong complement activators such as cobra venom factor (CVF) or pathological conditions such as sepsis. On the other hand, TLR activation may also regulate complement protein biosynthesis and receptor expression (modified from <xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al 2007</xref>).</p>
</caption>
<graphic alternate-form-of="fig2-0192623311428478" xlink:href="10.1177_0192623311428478-fig2.tif"/>
</fig>
<p>Activated complement achieves its biological effect by promoting inflammation through the generation of C3a and C5a, referred to as anaphylatoxins, by opsonization of target cells or activating surfaces and by formation of the membrane attack complex (<xref ref-type="bibr" rid="bibr15-0192623311428478">Dunkelberger and Song 2010a</xref>). Apart from these effector functions, complement also regulates adaptive immune responses (<xref ref-type="bibr" rid="bibr16-0192623311428478">Dunkelberger and Song 2010b</xref>). For example, complement is well known to be a natural adjuvant for B cell activation and antibody production (<xref ref-type="bibr" rid="bibr12-0192623311428478">Carroll 2000</xref>, <xref ref-type="bibr" rid="bibr13-0192623311428478">2004</xref>; <xref ref-type="bibr" rid="bibr20-0192623311428478">Fearon and Carroll 2000</xref>). This effect on B cell biology is achieved through multiple mechanisms, including lowering the threshold of B cell receptor activation, facilitating antigen retention on follicular dendritic cells, and promoting memory B cell survival (<xref ref-type="bibr" rid="bibr20-0192623311428478">Fearon and Carroll 2000</xref>; <xref ref-type="bibr" rid="bibr31-0192623311428478">Holers 2005</xref>). Recent evidence has suggested that complement also plays a regulatory role in T cell immune responses, although the mechanisms by which complement exerts this effect remain to be fully delineated (<xref ref-type="bibr" rid="bibr16-0192623311428478">Dunkelberger and Song 2010b</xref>). Most evidence supports a prominent role of the anaphylatoxins, working through their cognate G protein coupled receptors, in regulating the function and behavior of antigen-presenting cells, either directly or indirectly (<xref ref-type="bibr" rid="bibr16-0192623311428478">Dunkelberger and Song 2010b</xref>). Finally, complement is also known to play a role in “waste disposal,” namely, in the processing and removal of apoptotic cells and immune complexes (<xref ref-type="bibr" rid="bibr80-0192623311428478">Walport 2001a</xref>, <xref ref-type="bibr" rid="bibr81-0192623311428478">2001b</xref>). This hypothesis is supported by the clinical observation that deficiency of the early complement components, particularly of the classical pathways, such as C1q, C4, and C2, is a high-penetrance risk factor for developing systemic lupus erythematosus (SLE) (<xref ref-type="bibr" rid="bibr80-0192623311428478">Walport 2001a</xref>, <xref ref-type="bibr" rid="bibr81-0192623311428478">2001b</xref>). Furthermore, mice deficient in C1q and C4 also developed autoimmune diseases resembling human SLE with characteristic findings such as glomerulonephritis and appearance of high titer autoantibodies (<xref ref-type="bibr" rid="bibr10-0192623311428478">Botto et al. 1998</xref>; <xref ref-type="bibr" rid="bibr14-0192623311428478">Chen, Koralov, and Kelsoe 2000</xref>; <xref ref-type="bibr" rid="bibr62-0192623311428478">Paul et al. 2002</xref>).</p>
<p>While the pro-inflammatory and cytolytic activities of complement are needed to provide necessary host defense against pathogenic infections, excessive and uncontrolled complement activation has the potential to cause severe tissue injury. This is especially true considering that the alternative pathway is constitutively active and has the ability to undergo self-amplification. To prevent these undesirable consequences, host cells use a number of fluid-phase and membrane-bound regulators that function to inhibit complement activation on autologous cells (<xref ref-type="bibr" rid="bibr43-0192623311428478">Kim and Song 2006</xref>). The membrane-bound complement regulators include decay-accelerating factor (DAF), membrane cofactor protein (MCP), complement receptor-1 (CR1), and CD59. Fluid-phase regulators include factor H, C4-binding protein, and factor I. Except CD59, which is an inhibitor of membrane attack complex formation in the terminal stage of complement activation, all the aforementioned proteins work by inhibiting the activity of C3 and C5 convertases. Inhibition of C3 convertase activity is achieved by one of two ways: (1) promoting the dissociation (“decay acceleration”) of the two partners in the C3 convertases, namely, C4b and C2a in C4b2a and C3b and Bb in C3bBb; this activity is provided by DAF, CR1, and factor H; and (2) proteolytic degradation of C4b and C3b by factor I. The activity of factor I requires C4-binding protein (for C4b cleavage) or fH, MCP, CR1 (for C3b cleavage) as a cofactor. The latter activity is referred to as cofactor activity by the concerned complement regulators (<xref ref-type="bibr" rid="bibr43-0192623311428478">Kim and Song 2006</xref>).</p>
<p>Under normal physiological conditions, a fine balance between complement activation and regulation is maintained. Not surprisingly, when this delicate balance is disturbed, there are significant consequences to human health. On the one hand, genetic deficiencies of key complement components will render the affected individuals susceptible to opportunistic infections (<xref ref-type="bibr" rid="bibr80-0192623311428478">Walport 2001a</xref>, <xref ref-type="bibr" rid="bibr81-0192623311428478">2001b</xref>), and on the other, dysfunctional complement regulators can result in uncontrolled complement activation and attack of self tissues, leading to autoimmune and inflammatory diseases (<xref ref-type="bibr" rid="bibr43-0192623311428478">Kim and Song 2006</xref>). For example, deficiency of DAF and CD59 on hematopoietic stem cells causes the human hematological disorder paroxysmal nocturnal hematoglobinutia, which is characterized by sensitivity of red blood cells to autologous complement attack and lysis mediated by the alternative pathway (<xref ref-type="bibr" rid="bibr57-0192623311428478">Parker 1996</xref>). Mutations in factor H and MCP have been found to be associated with atypical hemolytic uremic syndrome and C3 glomerulopathy (<xref ref-type="bibr" rid="bibr22-0192623311428478">Fremeaux-Bacchi et al. 2006</xref>; <xref ref-type="bibr" rid="bibr46-0192623311428478">Le Quintrec et al. 2010</xref>; <xref ref-type="bibr" rid="bibr37-0192623311428478">Kavanagh, Richards, and Atkinson 2008</xref>). The importance of membrane complement regulators has also been demonstrated by studies of knockout mice lacking key complement regulators. Gene deletion of factor H resulted in uncontrolled systemic complement activation via the alternative pathway and secondary C3 and factor B deficiency, leading to age-dependent C3 glomerulopathy with features resembling human membranoproliferative glomerulonephritis (<xref ref-type="bibr" rid="bibr63-0192623311428478">Pickering et al. 2002</xref>). In our own studies of DAF knockout (DAF<sup>–/–</sup>) mice, we showed that mice deficient in DAF displayed increased sensitivity to anti-GBM glomerulonephritis and renal ischemia reperfusion injury (<xref ref-type="bibr" rid="bibr70-0192623311428478">Sogabe et al. 2001</xref>; <xref ref-type="bibr" rid="bibr83-0192623311428478">Yamada et al. 2004</xref>). Furthermore, DAF deficiency significantly exacerbated the autoimmune disease phenotype of MRL/lpr mice (<xref ref-type="bibr" rid="bibr50-0192623311428478">Miwa et al. 2002</xref>). Thus, while mice in a MRL/lpr mouse colony maintained at our animal facility generally had low incidence of dermatitis—and when they did, their skin lesions were usually very small—MRL/lpr mice deficient in DAF developed severe skin inflammation, often with large open lesions, at high prevalence (<xref ref-type="bibr" rid="bibr50-0192623311428478">Miwa et al. 2002</xref>). This phenotype was shown to reflect increased complement-dependent tissue injury in the absence of DAF, as further deletion of the C3 gene in DAF-deficient MRL/lpr mice rescued the exacerbated dermatitis phenotype (<xref ref-type="bibr" rid="bibr51-0192623311428478">Miwa et al. 2007</xref>).</p>
</sec>
<sec id="section2-0192623311428478">
<title>Toll-Like Receptors</title>
<p>Unlike soluble complement proteins that act as fluid-phase sentinels of pathogen infection, mammalian Toll-like receptors (TLRs) are a group of structurally related molecules that are expressed on the cell surface and serve as pattern recognition receptors (PRRs) to detect the presence of microbial infection (<xref ref-type="bibr" rid="bibr73-0192623311428478">Takeda, Kaisho, and Akira 2003</xref>; <xref ref-type="bibr" rid="bibr48-0192623311428478">Medzhitov 2001</xref>; <xref ref-type="bibr" rid="bibr52-0192623311428478">Modlin 2002</xref>). TLRs were initially identified based on homology to the <italic>Drosophila</italic> Toll receptor (<xref ref-type="bibr" rid="bibr67-0192623311428478">Rock et al. 1998</xref>). Mutant <italic>Drosophila</italic> carrying loss-of-function mutations in the Toll receptor were highly susceptible to fungi infection and unable to produce an anti-fungal peptide (<xref ref-type="bibr" rid="bibr47-0192623311428478">Lemaitre et al. 1996</xref>; Hoffman 2003). This provided the first evidence for the existence of innate cellular receptors that can sense and respond to microbial infection. Subsequently, a human homolog of Toll was identified and shown to be capable of inducing the production of inflammatory cytokines and costimulatory molecules (<xref ref-type="bibr" rid="bibr49-0192623311428478">Medzhitov, Preston-Hurlburt, and Janeway 1997</xref>). Later, a loss-of-function mutation of the murine homolog of the human Toll was identified in lipopolysaccharide (LPS)-hyporesponsive mice (<xref ref-type="bibr" rid="bibr64-0192623311428478">Poltorak et al. 1998</xref>; <xref ref-type="bibr" rid="bibr32-0192623311428478">Hoshino et al. 1999</xref>). These studies have established that Toll or Toll-like receptors are evolutionarily conserved pattern recognition receptors that can sense microbial pathogens and trigger direct innate immune responses in the host.</p>
<p>More than ten members of TLRs have been identified in humans and mice (<xref ref-type="bibr" rid="bibr4-0192623311428478">Akira, Uematsu, and Takeuchi 2006</xref>; <xref ref-type="bibr" rid="bibr58-0192623311428478">Pasare and Medzhitov 2003a</xref>; Takeda 2005). These TLRs have been found to recognize different microbial and, in some cases, endogenous ligands. For example, TLR4 can be activated by LPS from gram-negative bacteria, heat shock proteins (<xref ref-type="bibr" rid="bibr64-0192623311428478">Poltorak et al. 1998</xref>; <xref ref-type="bibr" rid="bibr32-0192623311428478">Hoshino et al. 1999</xref>; Takeda 2005; <xref ref-type="bibr" rid="bibr55-0192623311428478">Ohashi et al. 2000</xref>), and the anti-cancer drug taxol (<xref ref-type="bibr" rid="bibr41-0192623311428478">Kawasaki, Gomi, and Nishijima 2001</xref>; Kawasake et al. 2000; <xref ref-type="bibr" rid="bibr74-0192623311428478">Takeuchi and Akira 2001</xref>; <xref ref-type="bibr" rid="bibr11-0192623311428478">Byrd-Leifer et al. 2001</xref>). TLR2 can be activated by the yeast cell wall component zymosan and lipoteichoic acid from gram-positive bacteria (<xref ref-type="bibr" rid="bibr74-0192623311428478">Takeuchi and Akira 2001</xref>; <xref ref-type="bibr" rid="bibr77-0192623311428478">Underhill et al. 1999</xref>; <xref ref-type="bibr" rid="bibr69-0192623311428478">Schwandner et al. 1999</xref>; <xref ref-type="bibr" rid="bibr76-0192623311428478">Takeuchi et al. 1999</xref>; <xref ref-type="bibr" rid="bibr79-0192623311428478">Volman, Hendriks, and Goris 2005</xref>). TLR3 is activated by double-stranded RNAs from viruses, and TLR9 recognizes CpG DNA motifs present in viruses and bacteria (<xref ref-type="bibr" rid="bibr5-0192623311428478">Alexopoulou et al. 2001</xref>; <xref ref-type="bibr" rid="bibr2-0192623311428478">Akira and Takeda 2004</xref>; <xref ref-type="bibr" rid="bibr29-0192623311428478">Hemmi et al. 2000</xref>). Available evidence indicates that TLRs involved in the recognition of molecular structures unique to bacterial and fungal cells (TLR1, TLR2, TLR4, TLR5, and TLR6) are localized to the plasma membrane and can be recruited to phagosomes, whereas TLRs that recognize viral and bacterial nucleic acids (TLR3, TLR7, and TLR9) are localized in intracellular compartments (<xref ref-type="bibr" rid="bibr73-0192623311428478">Takeda, Kaisho, and Akira 2003</xref>; <xref ref-type="bibr" rid="bibr75-0192623311428478">Takeda and Akira 2005</xref>).</p>
<p>Structurally, TLRs contain extracellular leucine-rich repeats responsible for ligand binding, transmembrane domains, and cytoplasmic Toll/interleukin-1 receptor (TIR) domains required for initiating intracellular signaling (<xref ref-type="bibr" rid="bibr38-0192623311428478">Kawai and Akira 2006</xref>). Ligand-mediated activation of TLRs leads to receptor dimerization, recruitment of adaptor molecules, and activation of various protein kinases (<xref ref-type="bibr" rid="bibr2-0192623311428478">Akira and Takeda 2004</xref>; <xref ref-type="bibr" rid="bibr38-0192623311428478">Kawai and Akira 2006</xref>). These events culminate in the activation of nuclear factor-kB (NF-κB), activation protein-1 (AP-1), and interferon regulatory factor 3 (INF3), transcription factors that regulate the expression of inflammatory cytokines IL-6 (IL-8), TNF-α, IL-1β, and IL-12, as well as type I interferons- IFN-β and multiple forms of IFN-α (<xref ref-type="bibr" rid="bibr2-0192623311428478">Akira and Takeda 2004</xref>; <xref ref-type="bibr" rid="bibr38-0192623311428478">Kawai and Akira 2006</xref>). One of the key adaptor molecules that have been shown to be critical for TLR signaling is MyD88 (<xref ref-type="bibr" rid="bibr38-0192623311428478">Kawai and Akira 2006</xref>; <xref ref-type="bibr" rid="bibr25-0192623311428478">Hayashi et al. 2001</xref>; <xref ref-type="bibr" rid="bibr28-0192623311428478">Hemmi et al. 2002</xref>; <xref ref-type="bibr" rid="bibr39-0192623311428478">Kawai et al. 2001</xref>; <xref ref-type="bibr" rid="bibr23-0192623311428478">Hacker et al. 2000</xref>; <xref ref-type="bibr" rid="bibr68-0192623311428478">Schnare et al. 2000</xref>). MyD88 is required for the activation of all TLRs except TLR3, which signals via a MyD88-independent pathway (<xref ref-type="bibr" rid="bibr2-0192623311428478">Akira and Takeda 2004</xref>; <xref ref-type="bibr" rid="bibr38-0192623311428478">Kawai and Akira 2006</xref>). The MyD88-dependent pathway primarily controls the production of inflammatory cytokines whereas the MyD88-independent pathway regulates the production of anti-viral interferons (<xref ref-type="bibr" rid="bibr2-0192623311428478">Akira and Takeda 2004</xref>; <xref ref-type="bibr" rid="bibr38-0192623311428478">Kawai and Akira 2006</xref>). Notably, both MyD88-dependent and -independent pathways can be operative in a single TLR (e.g., TLR4), and either pathway is sufficient to cause co-stimulatory molecule (CD40, CD80, CD86) and MHCII expression on antigen-presenting cells (APCs) (<xref ref-type="bibr" rid="bibr2-0192623311428478">Akira and Takeda 2004</xref>; <xref ref-type="bibr" rid="bibr36-0192623311428478">Kaisho et al. 2001</xref>).</p>
<p>In addition to producing inflammatory cytokines and anti-viral interferons, activation of TLRs also elicits adaptive immune responses (<xref ref-type="bibr" rid="bibr60-0192623311428478">Pasare and Medzhitov 2004</xref>; <xref ref-type="bibr" rid="bibr34-0192623311428478">Iwasaki and Medzhitov 2004</xref>; <xref ref-type="bibr" rid="bibr3-0192623311428478">Akira, Takeda, and Kaisho 2001</xref>; <xref ref-type="bibr" rid="bibr6-0192623311428478">Barton and Medzhitov 2002</xref>). A key mechanism in the regulation of adaptive immunity by TLRs is the up-regulation of co-stimulatory molecules on APCs (<xref ref-type="bibr" rid="bibr34-0192623311428478">Iwasaki and Medzhitov 2004</xref>). Of interest, MyD88-deficient mouse APCs were still capable of expressing co-stimulatory molecules in response to TLR ligation (<xref ref-type="bibr" rid="bibr36-0192623311428478">Kaisho et al. 2001</xref>; <xref ref-type="bibr" rid="bibr3-0192623311428478">Akira, Takeda, and Kaisho 2001</xref>), yet these mice displayed profound defects in adaptive immune responses (<xref ref-type="bibr" rid="bibr36-0192623311428478">Kaisho et al. 2001</xref>; <xref ref-type="bibr" rid="bibr65-0192623311428478">Prinz et al. 2006</xref>). This suggested that both inflammatory cytokines and co-stimulatory molecules are necessary for generating optimal adaptive immune responses. It has been demonstrated in an in vitro T cell proliferation assay that TLR-induced inflammatory cytokines, of which IL-6 was shown to be an essential component, functioned to reverse the inhibitory effect of T regulatory cells (Treg) during T cell priming (<xref ref-type="bibr" rid="bibr59-0192623311428478">Pasare and Medzhitov 2003b</xref>, <xref ref-type="bibr" rid="bibr60-0192623311428478">2004</xref>). More recently, IL-6 has been established as a master cytokine that, together with TGF-β, drives the differentiation of a new class of IL-17-producing T helper cells referred to as Th-17 cells (<xref ref-type="bibr" rid="bibr78-0192623311428478">Veldhoen et al. 2006</xref>; <xref ref-type="bibr" rid="bibr7-0192623311428478">Bettelli et al. 2006</xref>). Th-17 cells are highly pro-inflammatory and are now widely recognized as playing a critical role in a variety of autoimmune diseases (<xref ref-type="bibr" rid="bibr72-0192623311428478">Steinman 2007</xref>; <xref ref-type="bibr" rid="bibr8-0192623311428478">Bettelli, Oukka, and Kuchroo 2007</xref>). In addition to IL-6, TNF-α and IL-1β as well as inhibition of IFN-γ and IL-12 have been shown to promote Th-17 differentiation (<xref ref-type="bibr" rid="bibr78-0192623311428478">Veldhoen et al. 2006</xref>; <xref ref-type="bibr" rid="bibr7-0192623311428478">Bettelli et al. 2006</xref>; <xref ref-type="bibr" rid="bibr72-0192623311428478">Steinman 2007</xref>; <xref ref-type="bibr" rid="bibr8-0192623311428478">Bettelli, Oukka, and Kuchroo 2007</xref>). It was also demonstrated that IL-6 drives Th-17 cell differentiation at least in part through up-regulation of IL-23R on and IL-21 production by Th-17 cells, thus generating a paracrine and autocrine amplification loop in Th-17 cell differentiation (<xref ref-type="bibr" rid="bibr85-0192623311428478">Zhou et al. 2007</xref>; <xref ref-type="bibr" rid="bibr54-0192623311428478">Nurieva et al. 2007</xref>; <xref ref-type="bibr" rid="bibr45-0192623311428478">Korn et al. 2007</xref>).</p>
</sec>
<sec id="section3-0192623311428478">
<title>Crosstalk between Complement and TLRs</title>
<p>Given that both the complement system and TLRs are co-evolved to detect and respond to pathogenic infections, it is not surprising that many microbial components and signature molecules are recognized by both forms of innate immunity. For example, LPS is the prototypical ligand for TLR4 and a well-known complement activator (<xref ref-type="bibr" rid="bibr9-0192623311428478">Bjornson and Bjornson 1977</xref>; <xref ref-type="bibr" rid="bibr53-0192623311428478">Morrison and Kline 1977</xref>). Zymosan, a component of yeast cell wall, is a strong alternative pathway complement activator as well as a ligand for TLR2/6 (<xref ref-type="bibr" rid="bibr79-0192623311428478">Volman, Hendriks, and Goris 2005</xref>). Until recently, the potential interaction between the two innate immune systems, when activated coincidentally, has not received much attention despite the fact that the biology of complement and TLRs has each been studied extensively. Using DAF<sup>–/– </sup>mice, we have characterized a striking interaction between complement and TLR signaling in vivo (<xref ref-type="bibr" rid="bibr84-0192623311428478">Figure 2; Zhang et al. 2007</xref>). The realization of a synergistic regulation of TLR response by complement in this model was somewhat fortuitous, and experiments that led to this conclusion were catalyzed by the unexpected observation that LPS injection into DAF<sup>–/– </sup>mice produced marked elevated levels of pro-inflammatory cytokines than it did in normal mice (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). In fact, our expectation of the initial experiment had been exactly the opposite based on published reports that DAF was an LPS-binding protein (<xref ref-type="bibr" rid="bibr27-0192623311428478">Heine et al. 2001</xref>; El-Aamalouti et al. 1997, 1999). We hypothesized that DAF, a glycosylphosphatidylinositol (GPI)-anchored membrane protein, may function as an LPS coreceptor to facilitate TLR4 signaling. A similar role has been established for CD14, also a GPI-anchored membrane protein whose deficiency in mice compromised LPS-induced TLR4 activation (<xref ref-type="bibr" rid="bibr26-0192623311428478">Haziot et al. 1996</xref>). Thus, had our original hypothesis been correct, we would have observed decreased LPS-dependent cytokine production mediated by TLR4 signaling. Instead, we found LPS-treated DAF<sup>–/– </sup>mice had significantly elevated plasma IL-6, TNF-α, and IL-1β levels compared with wild-type (WT) mice. On the other hand, plasma IL-12 level in DAF<sup>–/– </sup>mice was lower than that of WT mice (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>).</p>
<p>Enhanced production of pro-inflammatory cytokines in DAF<sup>–/– </sup>mice occurred at the transcriptional level as evidenced by increased IL-6 mRNA synthesis in the spleen, lung, and fat tissues of DAF<sup>–/– </sup>mice (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). The difference in IL-6 mRNA levels between WT and DAF<sup>–/– </sup>mice was detectible as early as one hour after LPS injection. Because LPS is a well-known complement activator and DAF inhibits complement activation, we wondered if the phenotype of DAF<sup>–/– </sup>mice was related to increased complement activation. To test this possibility, we investigated the LPS responses of DAF<sup>–/– </sup>mice that were deficient in C3. This experiment showed that the phenotype of DAF<sup>–/– </sup>mice was indeed dependent on complement. Thus, unlike DAF<sup>–/– </sup>mice, DAF<sup>–/– </sup>C3<sup>–/–</sup> mice had normal plasma levels of IL-6, TNF-α, IL-1β, and IL-12 after LPS challenge (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). Measurement of activated C3 fragments in the plasma after LPS challenge confirmed that DAF<sup>–/– </sup>mice were more sensitive to LPS-induced complement activation. To directly demonstrate that enhanced complement activation was responsible for increased production of cytokines in DAF<sup>–/– </sup>mice after LPS challenge, WT mice were simultaneously challenged with LPS and cobra venom factor (CVF), a potent complement activator. Significantly, while CVF treatment alone did not induce appreciable amount of IL-6 or IL-12 production in WT mice, it synergized with LPS to cause a dramatic increase in IL-6 production while profoundly suppressing IL-12 biosynthesis (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). This finding thus recapitulated the phenotype of LPS-treated DAF<sup>–/– </sup>mice and provided further support for a regulatory effect of complement on TLR4 signaling.</p>
<p>Several interesting questions arose from these initial observations regarding the mechanism of action of complement and the extent to which TLR-complement interactions occurred. Subsequent experiments were therefore designed to address these questions. By using receptor antagonists and gene knockout mice, it was established that the regulatory effect of complement on TLR4-induced cytokine production in LPS-treated DAF<sup>–/– </sup>mice or LPS/CVF cotreated WT mice was mediated mainly by the C5a receptor (C5aR) and, to a lesser extent, the C3a receptor (C3aR) (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). Further analysis also revealed that the hyper-LPS response phenotype of DAF<sup>–/– </sup>mice was correlated with increased NF-kB and mitogen-activated protein kinase activation in the spleens of LPS-treated mice. It was notable that while complement enhanced LPS-induced IL-6, TNF-α, and IL-1β production, it inhibited IL-12 production in the same experiments (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). The finding that complement suppressed TLR4-mediated IL-12 production both in DAF<sup>–/– </sup>and WT mice was consistent with previous works showing a negative regulation by C5a on IL-12 and IL-23 biosynthesis in murine peritoneal macrophages (<xref ref-type="bibr" rid="bibr24-0192623311428478">Hawlisch et al. 2005</xref>). These results together implied a differential regulatory mechanism by complement on IL-12 than those operative in the regulation of the proinflammatory cytokines such as IL-6 and TNF-α. It was demonstrated that the inhibitory effect of complement on IL-12 production was at least partially mediated by IL-10. As it turned out, in addition to IL-6, TNF-α, and IL-1β, complement also synergized with LPS to enhance IL-10 production both in vivo and in isolated peritoneal macrophages (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). Complement-mediated inhibition of IL-12 biosynthesis in vivo was attenuated in IL-10 knockout mice, and antibody blocking of IL-10 in cultured peritoneal macrophages also blunted the inhibitory effect of C5a on LPS-induced IL-12 production (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). In other studies using pharmacological approaches, it was found that the inhibitory effect of C5a on IL-12 biosynthesis in peritoneal macrophages was mediated by a phosphoinositol-3 kinase (PI3K)-dependent mechanism (<xref ref-type="bibr" rid="bibr24-0192623311428478">Hawlisch et al. 2005</xref>). However, the involvement of PI3K in this process was questioned by a subsequent study showing that the inhibitory effect of C5a on IL-12 production in murine peritoneal macrophages was still observed in PI3K knockout mice (<xref ref-type="bibr" rid="bibr56-0192623311428478">Okazaki et al. 2011</xref>). It is possible that redundant mechanisms exist, and in the absence of PI3K, other pathways may have compensated for the lack of PI3K-mediated signaling events.</p>
<p>Another question arising from the observed regulatory effect of complement on TLR4 signaling is whether complement also exerts a similar effect on the signaling pathways of other TLRs. We addressed this issue by testing the sensitivity of DAF<sup>–/– </sup>mice to several TLR ligands, including zymosan (for TLR2/6) and CpG (for TLR9), and by evaluating the sensitivity of WT mice to coincidental stimulation of the concerned TLR ligands and CVF. These experiments showed that complement could also impact the signaling of other TLRs, but the effect on specific cytokine production may not be identical to that observed in the case of TLR4 activation (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). Thus, while coincidental complement activation augmented IL-6 and suppressed IL-12 production induced by zymosan, it similarly suppressed IL-12 production but had no effect on IL-6 biosynthesis after mice were challenged with CpG (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>). Furthermore, in contrast to what has been observed in the regulation of TLR4 signaling by complement where C5aR seemed to play a major role, the suppressive effect of complement on CpG-triggered IL-12 production appeared to be mediated mainly by C3aR rather than by C5aR (<xref ref-type="bibr" rid="bibr84-0192623311428478">Zhang et al. 2007</xref>).</p>
<p>Interaction between complement and TLRs can occur both ways. While, as described previously, the complement anaphylatoxins augmented TLR-induced proinflammatory cytokine production, other studies have demonstrated that TLR activation could also increase complement protein synthesis and effector function. For example, in the RAW264.7 murine macrophage cell line, LPS treatment dramatically increased complement factor B gene transcription and protein synthesis (<xref ref-type="bibr" rid="bibr35-0192623311428478">Kaczorowski et al. 2010</xref>). A similar effect of LPS on factor B production could be observed in thioglycollate-elicited mouse peritoneal macrophages. This effect by LPS was TLR4-dependent and was mediated by TIR-domain-containing adapter-inducing interferon-β (TRIF), Jun N-terminal kinase (JNK), and NF-kB (<xref ref-type="bibr" rid="bibr35-0192623311428478">Kaczorowski et al. 2010</xref>). A screen of other TLR ligands showed that polyI:C, a double-strand RNA analog, and a ligand for TLR3 and cytosolic double-stranded RNA receptors also stimulated the up-regulation of factor B. The effect of polyI:C appeared to be mediated by the cytosolic receptors rather than by TLR3 but was also dependent on JNK and NF-kB (<xref ref-type="bibr" rid="bibr35-0192623311428478">Kaczorowski et al. 2010</xref>). In another recent study, an example was provided of a marked positive modulatory effect of TLR activation on cell sensitivity to C5a in vitro and in vivo. In this model, pre-exposure of peripheral blood mononuclear cells and whole blood to various TLR ligands or bacteria enhanced C5a-mediated pro-inflammatory responses (<xref ref-type="bibr" rid="bibr66-0192623311428478">Raby et al. 2011</xref>). This effect was dependent on TLR4 but did not involve up-regulation of C5aR. Instead, TLR activation was found to reduce the activity of C5L2, a second C5a receptor that in some studies has been described as a decoy receptor to negatively modulate C5aR function (<xref ref-type="bibr" rid="bibr66-0192623311428478">Raby et al. 2011</xref>). The TLR-induced hypersensitivity to C5a was mimicked by C5L2 blockade and was abolished in C5L2 knockout mice. Furthermore, TLR-dependent suppression of C5L2 activity could be traced to reduced C5L2 expression (<xref ref-type="bibr" rid="bibr66-0192623311428478">Raby et al. 2011</xref>).</p>
<p>Because cytokines produced by antigen-presenting cells in response to TLR activation play critical roles in T cell differentiation, we investigated whether the synergistic interaction between complement and TLRs might also have consequences for T cell immune responses. Specifically, the inflammatory cytokine IL-6 has been shown to be a key driving force for Th-17 cell polarization. Using an in vitro mouse T cell activation system stimulated by plate-bound anti-CD3 and soluble anti-CD28 antibodies, we showed that T cells activated and cultured in the presence of 5% serum from mice that had been cotreated with LPS and CVF or C5a contained a higher percentage of Th-17 effector cells than T cells activated in the presence of sera from mice treated with LPS, CVF, or C5a alone (<xref ref-type="bibr" rid="bibr19-0192623311428478">Fang et al. 2009</xref>). This effect was critically dependent on IL-6 in the mouse serum as addition of an IL-6-neutralizing antibody prevented the differentiation of Th-17 cells (<xref ref-type="bibr" rid="bibr19-0192623311428478">Fang et al. 2009</xref>). Furthermore, serum from C3<sup>–/–</sup> or C5aR<sup>–/–</sup> mice cotreated with LPS and C5a did not show enhanced activity in polarizing Th-17 cells, confirming that a higher serum IL-6 level, produced by TLR4 and complement interaction in a C5aR-dependent manner, was responsible for the observed effect on Th-17 differentiation (<xref ref-type="bibr" rid="bibr19-0192623311428478">Fang et al. 2009</xref>). Collectively, these results demonstrated that complement and TLR interaction may not only enhance the host innate immune response but also their adaptive immunity to pathogen infection. On the other hand, the interaction between the two innate immune components may also be exploited by certain pathogens to subvert the host immune attack as has been detailed in a recent study (<xref ref-type="bibr" rid="bibr82-0192623311428478">Wang et al. 2010</xref>). In this example, the periodontal pathogen <italic>Porphyromonas gingivalis</italic> produced a protease with C5 convertase activity that generated C5a without forming the harmful membrane attack complex (<xref ref-type="bibr" rid="bibr82-0192623311428478">Wang et al. 2010</xref>). The C5a, through ligation with its congate receptor C5aR on macrophages, then synergized with the TLR2 pathway to increase cAMP production, which in turn inhibited nitric oxide release, thus promoting the survival of <italic>P</italic>. <italic>gingivalis</italic> in the host (<xref ref-type="bibr" rid="bibr82-0192623311428478">Wang et al. 2010</xref>).</p>
</sec>
<sec id="section4-0192623311428478">
<title>Concluding Remarks</title>
<p>In summary, complement and TLRs are two important components of innate immunity. Although each has been studied extensively as a separate entity, given the fact that many microbial ligands and signature molecules are capable of activating both, it is likely that pathogen infection will simultaneously trigger both pathways in vivo. In some situations, endogenous ligands derived from damaged or altered self may also cause coincidental activation of the two pathways. Crosstalk between the two systems to enhance the immediate immune reaction to pathogen infection and to better prime the host in mounting a more robust adaptive immune response has obvious advantages from an evolutionary point of view. In other conditions, however, synergistic amplification of the inflammation response may be detrimental. Understanding the mechanisms and intricacies of such interactions may help to devise novel therapeutic strategies to prevent or treat overwhelming and life-threatening inflammatory conditions such as septic shock and trauma-induced systemic inflammation syndrome. Such knowledge may also benefit the effort to prevent infectious diseases by developing more effective vaccines or by specifically targeting immune subversion tactics of certain pathogens.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>I thank Dr. Takashi Miwa for help in manuscript preparation.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0192623311428478">
<p>The author(s) declared no potential conflicts of interests with respect to the authorship and/or publication of this article. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Work in the author’s laboratory has been supported by NIH grants GM092108, AI44970, AI85596, and AI49344.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agarwal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Cortes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pangburn</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Ram</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>An evaluation of the role of properdin in alternative pathway activation on <italic>Neisseria meningitidis</italic> and <italic>Neisseria gonorrhoeae</italic></article-title>. <source>J Immunol</source> <volume>185</volume>, <fpage>507</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr2-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Toll-like receptor signalling</article-title>. <source>Nat Rev Immunol</source> <volume>4</volume>, <fpage>499</fpage>–<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr3-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names> </name>
<name>
<surname>Kaisho</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Toll-like receptors: Critical proteins linking innate and acquired immunity</article-title>. <source>Nat Immunol</source> <volume>2</volume>, <fpage>675</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr4-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Uematsu</surname>
<given-names>S.</given-names> </name>
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Pathogen recognition and innate immunity</article-title>. <source>Cell</source> <volume>124</volume>, <fpage>783</fpage>–<lpage>801</lpage>.</citation>
</ref>
<ref id="bibr5-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexopoulou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Holt</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Flavell</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3</article-title>. <source>Nature</source> <volume>413</volume>, <fpage>732</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr6-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barton</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Control of adaptive immune responses by Toll-like receptors</article-title>. <source>Curr Opin Immunol</source> <volume>14</volume>, <fpage>380</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr7-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bettelli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carrier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Korn</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Strom</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Oukka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Kuchroo</surname>
<given-names>V. K.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells</article-title>. <source>Nature</source> <volume>441</volume>, <fpage>235</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr8-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bettelli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Oukka</surname>
<given-names>M.</given-names> </name>
<name>
<surname>Kuchroo</surname>
<given-names>V. K.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>T(H)-17 cells in the circle of immunity and autoimmunity</article-title>. <source>Nature Immunol</source> <volume>8</volume>, <fpage>345</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr9-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjornson</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Bjornson</surname>
<given-names>H. S.</given-names>
</name>
</person-group> (<year>1977</year>). <article-title>Activation of complement by opportunist pathogens and chemotypes of </article-title>
<source>Salmonella minnesota. Infect Immun</source> <volume>16</volume>, <fpage>748</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr10-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Botto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dell'Agnola</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bygrave</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>H. T.</given-names>
</name>
<name>
<surname>Petry</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P. P.</given-names>
</name>
<name>
<surname>Walport</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies</article-title>. <source>Nat Genet</source> <volume>19</volume>, <fpage>56</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr11-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byrd-Leifer</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Block</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names> </name>
<name>
<surname>Ding</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol</article-title>. <source>Eur J Immunol</source> <volume>31</volume>, <fpage>2448</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr12-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>The role of complement in B cell activation and tolerance</article-title>. <source>Adv Immunol</source> <volume>74</volume>, <fpage>61</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr13-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>A protective role for innate immunity in systemic lupus erythematosus</article-title>. <source>Nat Rev Immunol</source> <volume>4</volume>, <fpage>825</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr14-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Koralov</surname>
<given-names>S. B.</given-names> </name>
<name>
<surname>Kelsoe</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2</article-title>. <source>J Exp Med</source> <volume>192</volume>, <fpage>1339</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr15-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunkelberger</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2010a</year>). <article-title>Complement and its role in innate and adaptive immune responses</article-title>. <source>Cell Res</source> <volume>20</volume>, <fpage>34</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr16-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunkelberger</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2010b</year>). <article-title>Role and mechanism of action of complement in regulating T cell immunity</article-title>. <source>Mol Immunol</source> <volume>47</volume>, <fpage>2176</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr17-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Samalouti</surname>
<given-names>V. T.</given-names>
</name>
<name>
<surname>Schletter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brade</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Brade</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kusumoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rietschel</surname>
<given-names>E. T.</given-names>
</name>
<name>
<surname>Flad</surname>
<given-names>H. D.</given-names> </name>
<name>
<surname>Ulmer</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Detection of lipopolysaccharide (LPS)-binding membrane proteins by immuno-coprecipitation with LPS and anti-LPS antibodies</article-title>. <source>Eur J Biochem</source> <volume>250</volume>, <fpage>418</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr18-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Samalouti</surname>
<given-names>V. T.</given-names>
</name>
<name>
<surname>Schletter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chyla</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lentschat</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mamat</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Brade</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Flad</surname>
<given-names>H. D.</given-names>
</name>
<name>
<surname>Ulmer</surname>
<given-names>A. J.</given-names> </name>
<name>
<surname>Hamann</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Identification of the 80-kDa LPS-binding protein (LMP80) as decay-accelerating factor (DAF, CD55)</article-title>. <source>FEMS Immunol Med Microbiol</source> <volume>23</volume>, <fpage>259</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr19-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Miwa</surname>
<given-names>T.</given-names> </name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Complement promotes the development of inflammatory Th17 cells through synergistic interaction with TLR signaling and IL-6 production</article-title>. <source>Blood</source> <volume>114</volume>(<issue>5</issue>):<fpage>1005</fpage>–<lpage>015</lpage>.</citation>
</ref>
<ref id="bibr20-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fearon</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex</article-title>. <source>Annu Rev Immunol</source> <volume>18</volume>, <fpage>393</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr21-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Cortes</surname>
<given-names>C.</given-names> </name>
<name>
<surname>Pangburn</surname>
<given-names>M. K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement</article-title>. <source>Immunobiol</source> <volume>215</volume>, <fpage>932</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr22-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fremeaux-Bacchi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Moulton</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Kavanagh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dragon-Durey</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Blouin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Caudy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arzouk</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cleper</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Francois</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guest</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pourrat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Seligman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fridman</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Loirat</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Atkinson</surname>
<given-names>J. P</given-names>
</name>
</person-group>. (<year>2006</year>). <article-title>Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome</article-title>. <source>J Am Soc Nephrol</source> <volume>17</volume>, <fpage>2017</fpage>–<lpage>025</lpage>.</citation>
</ref>
<ref id="bibr23-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hacker</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vabulas</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hoshino</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6</article-title>. <source>J Exp Med</source> <volume>192</volume>, <fpage>595</fpage>–<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr24-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hawlisch</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Belkaid</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Baelder</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hildeman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gerard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kohl</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2005</year>) <article-title>C5a negatively regulates toll-like receptor 4-induced immune responses</article-title>. <source>Immunity</source> <volume>22</volume>, <fpage>415</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr25-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Ozinsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hawn</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Goodlett</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Underhill</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Aderem</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5</article-title>. <source>Nature</source> <volume>410</volume>, <fpage>1099</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr26-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haziot</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ferrero</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kontgen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hijiya</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Goyert</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice</article-title>. <source>Immunity</source> <volume>4</volume>, <fpage>407</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr27-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ulmer</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>El-Samalouti</surname>
<given-names>V. T.</given-names>
</name>
<name>
<surname>Lentschat</surname>
<given-names>A.</given-names> </name>
<name>
<surname>Hamann</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Decay-accelerating factor (DAF/CD55) is a functional active element of the LPS receptor complex</article-title>. <source>J Endotoxin Res</source> <volume>7</volume>, <fpage>227</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr28-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemmi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kaisho</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sanjo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hoshino</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tomizawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway</article-title>. <source>Nat Immunol</source> <volume>3</volume>, <fpage>196</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr29-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemmi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kaisho</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sanjo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hoshino</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names> </name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>A Toll-like receptor recognizes bacterial DNA</article-title>. <source>Nature</source> <volume>408</volume>, <fpage>740</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr30-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The immune response of </article-title>
<source>Drosophila. Nature</source> <volume>426</volume>, <fpage>33</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr31-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holers</surname>
<given-names>V. M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Complement receptors and the shaping of the natural antibody repertoire</article-title>. <source>Springer Semin Immunopathol</source> <volume>26</volume>, <fpage>405</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr32-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoshino</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sanjo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product</article-title>. <source>J Immunol</source> <volume>162</volume>, <fpage>3749</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr33-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hourcade</surname>
<given-names>D. E.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>The role of properdin in the assembly of the alternative pathway C3 convertases of complement</article-title>. <source>J Biol Chem</source> <volume>281</volume>, <fpage>2128</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr34-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwasaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Toll-like receptor control of the adaptive immune responses</article-title>. <source>Nat Immunol</source> <volume>5</volume>, <fpage>987</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr35-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaczorowski</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Afrazi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Gill</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Edmonds</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names> </name>
<name>
<surname>Billiar</surname>
<given-names>T. R.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Pivotal advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms</article-title>. <source>J Leukoc Biol</source> <volume>88</volume>, <fpage>609</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr36-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaisho</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hoshino</surname>
<given-names>K.</given-names> </name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Endotoxin-induced maturation of MyD88-deficient dendritic cells</article-title>. <source>J Immunol</source> <volume>166</volume>, <fpage>5688</fpage>–<lpage>694</lpage>.</citation>
</ref>
<ref id="bibr37-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavanagh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>A.</given-names> </name>
<name>
<surname>Atkinson</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Complement regulatory genes and hemolytic uremic syndromes</article-title>. <source>Annu Rev Med</source> <volume>59</volume>, <fpage>293</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr38-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>TLR signaling</article-title>. <source>Cell Death Differ</source> <volume>13</volume>, <fpage>816</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr39-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Muhlradt</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hoshino</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes</article-title>. <source>J Immunol</source> <volume>167</volume>, <fpage>5887</fpage>–<lpage>894</lpage>.</citation>
</ref>
<ref id="bibr40-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shimazu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miyake</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nishijima</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol</article-title>. <source>J Biol Chem</source> <volume>275</volume>, <fpage>2251</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr41-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gomi</surname>
<given-names>K.</given-names> </name>
<name>
<surname>Nishijima</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Cutting edge: Gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol</article-title>. <source>J Immunol</source> <volume>166</volume>, <fpage>11</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr42-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemper</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Atkinson</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Hourcade</surname>
<given-names>D. E.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Properdin: Emerging roles of a pattern-recognition molecule</article-title>. <source>Annu Rev Immunol</source> <volume>28</volume>, <fpage>131</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr43-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Membrane complement regulatory proteins</article-title>. <source>Clin Immunol</source> <volume>118</volume>, <fpage>127</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr44-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Miwa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names> </name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement</article-title>. <source>Blood</source> <volume>111</volume>, <fpage>732</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr45-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korn</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bettelli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Awasthi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jager</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Strom</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Oukka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kuchroo</surname>
<given-names>V. K.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells</article-title>. <source>Nature</source> <volume>448</volume>, <fpage>484</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr46-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Quintrec</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roumenina</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Noris</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fremeaux-Bacchi</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes</article-title>. <source>Semin Thromb Hemost</source> <volume>36</volume>, <fpage>641</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr47-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemaitre</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Michaut</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Reichhart</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in <italic>Drosophila</italic> adults</article-title>. <source>Cell</source> <volume>86</volume>, <fpage>973</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr48-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Toll-like receptors and innate immunity</article-title>. <source>Nat Rev Immunol</source> <volume>1</volume>, <fpage>135</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr49-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Preston-Hurlburt</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Janeway</surname>
<given-names>C. A., </given-names>
<suffix>Jr</suffix>
</name>
</person-group> (<year>1997</year>). <article-title>A human homologue of the <italic>Drosophila</italic> Toll protein signals activation of adaptive immunity</article-title>. <source>Nature</source> <volume>388</volume>, <fpage>394</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr50-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miwa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Werth</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Madaio</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Eisenberg</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice</article-title>. <source>Am J Pathol</source> <volume>161</volume>, <fpage>1077</fpage>–<lpage>086</lpage>.</citation>
</ref>
<ref id="bibr51-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miwa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gilkeson</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Eisenberg</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms</article-title>. <source>Am J Pathol</source> <volume>170</volume>, <fpage>1258</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr52-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modlin</surname>
<given-names>R. L.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Mammalian toll-like receptors</article-title>. <source>Ann Allergy Asthma Immunol</source> <volume>88</volume>, <fpage>543</fpage>–<lpage>47</lpage>; <comment>quiz</comment> <fpage>548</fpage>–<lpage>50</lpage>, <comment>83</comment>.</citation>
</ref>
<ref id="bibr53-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrison</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Kline</surname>
<given-names>L. F.</given-names>
</name>
</person-group> (<year>1977</year>). <article-title>Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS)</article-title>. <source>J Immunol</source> <volume>118</volume>, <fpage>362</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr54-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nurieva</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X. O.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Panopoulos</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schluns</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Watowich</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Jetten</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C</given-names>
</name>
</person-group>. (<year>2007</year>). <article-title>Essential autocrine regulation by IL-21 in the generation of inflammatory T cells</article-title>. <source>Nature</source> <volume>448</volume>, <fpage>480</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr55-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Burkart</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Flohe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kolb</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex</article-title>. <source>J Immunol</source> <volume>164</volume>, <fpage>558</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr56-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okazaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hazeki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nigorikawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hazeki</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>C5a controls TLR-induced IL-10 and IL-12 production independent of phosphoinositide 3-kinase</article-title>. <source>J Biochem</source> <volume>149</volume>, <fpage>265</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr57-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Molecular basis of paroxysmal nocturnal hemoglobinuria</article-title>. <source>Stem Cells</source> <volume>14</volume>, <fpage>396</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr58-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasare</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2003a</year>). <article-title>Toll-like receptors: Balancing host resistance with immune tolerance</article-title>. <source>Curr Opin Immunol</source> <volume>15</volume>, <fpage>677</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr59-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasare</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2003b</year>). <article-title>Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells</article-title>. <source>Science</source> <volume>299</volume>, <fpage>1033</fpage>–<lpage>036</lpage>.</citation>
</ref>
<ref id="bibr60-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasare</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Toll-dependent control mechanisms of CD4 T cell activation</article-title>. <source>Immunity</source> <volume>21</volume>, <fpage>733</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr61-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasare</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Toll-like receptors: Linking innate and adaptive immunity</article-title>. <source>Adv Exp Med Biol</source> <volume>560</volume>, <fpage>11</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr62-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paul</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pozdnyakova</surname>
<given-names>O. O.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Anti-DNA autoreactivity in C4-deficient mice</article-title>. <source>Eur J Immunol</source> <volume>32</volume>, <fpage>2672</fpage>–<lpage>679</lpage>.</citation>
</ref>
<ref id="bibr63-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pickering</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>H. T.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bygrave</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Walport</surname>
<given-names>M. J.</given-names> </name>
<name>
<surname>Botto</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H</article-title>. <source>Nat Genet</source> <volume>31</volume>, <fpage>424</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr64-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poltorak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Smirnova</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Van Huffel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Birdwell</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alejos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galanos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Freudenberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ricciardi-Castagnoli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Layton</surname>
<given-names>B.</given-names> </name>
<name>
<surname>Beutler</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene</article-title>. <source>Science</source> <volume>282</volume>, <fpage>2085</fpage>–<lpage>088</lpage>.</citation>
</ref>
<ref id="bibr65-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prinz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garbe</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mildner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gutcher</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wolter</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Piesche</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schroers</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kirschning</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Rochford</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Bruck</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Becher</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis</article-title>. <source>J Clin Invest</source> <volume>116</volume>, <fpage>456</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr66-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raby</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Holst</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Colmont</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Laumonnier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Coles</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Topley</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kohl</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Labeta</surname>
<given-names>M. O</given-names>
</name>
</person-group>. (<year>2011</year>). <article-title>Toll-like receptor activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2</article-title>. <source>Eur J Immunol</source> <issue>Jun 1</issue>. <comment>doi: 10.1002/eji.201041350. [Epub ahead of print</comment>
<comment>]</comment>
</citation>
</ref>
<ref id="bibr67-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rock</surname>
<given-names>F. L.</given-names>
</name>
<name>
<surname>Hardiman</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Timans</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Kastelein</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Bazan</surname>
<given-names>J. F.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>A family of human receptors structurally related to <italic>Drosophila</italic> Toll</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>95</volume>, <fpage>588</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr68-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schnare</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Holt</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names> </name>
<name>
<surname>Medzhitov</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88</article-title>. <source>Curr Biol</source> <volume>10</volume>, <fpage>1139</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr69-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwandner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dziarski</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wesche</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rothe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kirschning</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2</article-title>. <source>J Biol Chem</source> <volume>274</volume>, <fpage>17406</fpage>–<lpage>7409</lpage>.</citation>
</ref>
<ref id="bibr70-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sogabe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nangaku</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ishibashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Miwa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Madaio</surname>
<given-names>M. P.</given-names> </name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis</article-title>. <source>J Immunol</source> <volume>167</volume>, <fpage>2791</fpage>–<lpage>797</lpage>.</citation>
</ref>
<ref id="bibr71-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spitzer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Atkinson</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Hourcade</surname>
<given-names>D. E.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly</article-title>. <source>J Immunol</source> <volume>179</volume>, <fpage>2600</fpage>–<lpage>608</lpage>.</citation>
</ref>
<ref id="bibr72-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinman</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage</article-title>. <source>Nature Med</source> <volume>13</volume>, <fpage>139</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr73-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kaisho</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Toll-like receptors</article-title>. <source>Annu Rev Immunol</source> <volume>21</volume>, <fpage>335</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr74-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Toll-like receptors; their physiological role and signal transduction system</article-title>. <source>Int Immunopharmacol</source> <volume>1</volume>, <fpage>625</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr75-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Toll-like receptors in innate immunity</article-title>. <source>Int Immunol</source> <volume>17</volume>, <fpage>1</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr76-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hoshino</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sanjo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components</article-title>. <source>Immunity</source> <volume>11</volume>, <fpage>443</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr77-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Underhill</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Ozinsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hajjar</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>Bassetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aderem</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens</article-title>. <source>Nature</source> <volume>401</volume>, <fpage>811</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr78-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veldhoen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hocking</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Atkins</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Locksley</surname>
<given-names>R. M.</given-names> </name>
<name>
<surname>Stockinger</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells</article-title>. <source>Immunity</source> <volume>24</volume>, <fpage>179</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr79-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volman</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Hendriks</surname>
<given-names>T.</given-names> </name>
<name>
<surname>Goris</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Zymosan-induced generalized inflammation: Experimental studies into mechanisms leading to multiple organ dysfunction syndrome</article-title>. <source>Shock</source> <volume>23</volume>, <fpage>291</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr80-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walport</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2001a</year>). <article-title>Complement. First of two parts</article-title>. <source>N Engl J Med</source> <volume>344</volume>, <fpage>1058</fpage>–<lpage>066</lpage>.</citation>
</ref>
<ref id="bibr81-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walport</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2001b</year>). <article-title>Complement. Second of two parts</article-title>. <source>N Engl J Med</source> <volume>344</volume>, <fpage>1140</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr82-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Krauss</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Domon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hosur</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Magotti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Triantafilou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Triantafilou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lambris</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Hajishengallis</surname>
<given-names>G</given-names>
</name>
</person-group>. (<year>2010</year>). <article-title>Microbial hijacking of complement-Toll-like receptor crosstalk</article-title>. <source>Sci Signal</source> <volume>3</volume>(<issue>109</issue>):<comment>ra11</comment>.</citation>
</ref>
<ref id="bibr83-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miwa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nangaku</surname>
<given-names>M.</given-names> </name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Critical protection from renal ischemia reperfusion injury by CD55 and CD59</article-title>. <source>J Immunol</source> <volume>172</volume>, <fpage>3869</fpage>–<lpage>875</lpage>.</citation>
</ref>
<ref id="bibr84-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sfyroera</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lambris</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Wetsel</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Miwa</surname>
<given-names>T.</given-names> </name>
<name>
<surname>Song</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo</article-title>. <source>Blood</source> <volume>110</volume>, <fpage>228</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr85-0192623311428478">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>I. I.</given-names>
</name>
<name>
<surname>Spolski</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shenderov</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Egawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Littman</surname>
<given-names>D. R.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways</article-title>. <source>Nat Immunol</source> <volume>8</volume>, <fpage>967</fpage>–<lpage>74</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>